



REPORTED IHC / FISH / MOLECULAR PROFILING REQUEST FORM

HSL-AD LABORATORY USE ONLY

MATERIAL RECEIVED: _____

HSL-AD NUMBER: _____

DATE RECEIVED & INITIALS: _____

PATIENT / SAMPLE DETAILS

SURNAME: _____

SURGICAL ID: _____ BLOCK ID: _____

FORENAME: _____

BODY SITE: _____

DOB: _____

TUMOUR TYPE: _____

GENDER: F ☐ M ☐ DIFFERENT AT BIRTH ☐

PRIMARY ☐ METASTATIC ☐

REQUESTING LABORATORY/HOSPITAL & INVOICING DETAILS

CONSULTANT: _____

INVOICING DETAILS (if different)

ADDRESS: _____

CONTACT NAME: _____

ORGANISATION: _____

ADDRESS: _____

EMAIL: _____

PHONE: _____

PO NUMBER: _____

REPORTED IHC/FISH/MOLECULAR TESTS REQUESTED

HER2 IHC

- ☐ Breast*
☐ Gastric/Oesophageal*
☐ Biliary Tract*
☐ Colorectal*
☐ Gynae*
☐ Lung*
☐ Other*
☐ If Her-2 Negative reflex to PD-L1**

BREAST IHC

- ☐ ER ☐ PR
LUNG IHC
☐ ALK* ☐ ROS1*
OVARIAN IHC
☐ FOLR1
This FOLR1 testing service is funded by AbbVie UK Ltd for NHS patients

GASTRIC/GOJ IHC

- ☐ CLDN18.2
MELANOMA IHC
☐ BRAF V600E
PAN CANCER IHC
☐ MMR
☐ p16

FISH

HER2 (ERBB2)

- ☐ HER2 (ERBB2)
Breast
☐ MYC Amp

Lung

- ☐ ALK ☐ ROS1
☐ MET Amp ☐ RET

Head & Neck

- ☐ ETV6/NTRK3 ☐ NUTM
☐ MAML2 ☐ MYB

Lymphoma

- ☐ BCL2
☐ BCL6
☐ MYC***
☐ IRF4/DUSP22
☐ CCND1
☐ MALT1
☐ IGH

Pan Cancer

- ☐ NTRK1-3 ☐ FGFR1 Amp
☐ FGFR2 Amp ☐ FGFR2 Trans

Sarcoma

- ☐ CDK4 ☐ DDIT3
☐ EWSR1 ☐ MDM2
☐ PDGFB

Renal

- ☐ TFE3
☐ TFEB

Melanoma

- ☐ Four Probe

PD-L1 IHC

22C3 (Pembrolizumab)

- ☐ Breast (TNBC, CPS)
☐ Cervical (CPS)
☐ Gastric (CPS)
☐ Head & Neck (CPS)
☐ Lung (NSCLC, TPS)
☐ Oesophageal/GOJ (CPS)
☐ Urothelial (CPS)
☐ Other (CPS)
☐ Other (TPS)

SP142 (Atezolizumab)

- ☐ Breast (TNBC, IC)
☐ Lung (NSCLC, IC)
☐ Urothelial (IC)
☐ Other (IC)

28-8 (Nivolumab)

- ☐ Gastric/GOJ (CPS)
☐ Head & Neck (TPS)
☐ Melanoma (TPS)
☐ Oesophageal (SCC, TPS)
☐ Urothelial (TPS)
☐ Other (CPS)
☐ Other (TPS)

*Automatic confirmation by FISH for 2+ (Her-2) and weak/strong positive (ALK, ROS1) cases and as required.

**Reflex PD-L1 testing for Her-2 negative Breast adenocarcinoma (Agilent PharmDx 22C3 and Roche SP142).
Reflex PD-L1 testing for Her-2 negative GOJ adenocarcinoma (Agilent PharmDx 22C3 and 28-8).

***MYC FISH requests will be performed using breakapart and fusion probes. Automatic reflex to extended MYC FISH panel (IGK, IGL, MYC::BCL6) as required.

MOLECULAR PROFILING

HPV

- ☐ HPV Genotype Profiling (FFPE)

Comprehensive Profiling for High & Low Risk HPV Genotypes by DNA PCR

PROSIGNA

- ☐ Breast cancer risk stratification

NICE Approved Breast Cancer Prognostic Gene Signature Assay

- Testing on excision specimen recommended, testing on biopsy specimen only where neo-adjuvant therapy has been administered.
- This test is for ER positive, Her-2 negative breast cancer, min. 10% viable tumour.
- Tissue block and full pathology report must be sent alongside all requests.

IDYLLA

Rapid molecular testing for actionable therapeutic targets and MSI

- ☐ BRAF ☐ EGFR ☐ KRAS ☐ MSI
+/- NRAS/BRAF Reflex